Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues.
Bypassing therapy is usually necessary to control or prevent bleeding episodes in patients with haemophilia A or B and high-titre inhibitors. Factor VIII inhibitor bypassing activity (FEIBA) has a long history of successful use in the acute, surgical and prophylactic treatment settings, but safety concerns have made some reluctant to administer this bypassing agent. A review of the literature and clinical trial data show that FEIBA has a low prevalence of thrombosis, a low prevalence of anamnesis that does not impact haemostatic efficacy and an excellent record of pathogen safety and clinical tolerability.
Aledort
L M
LM
Mount Sinai School of Medicine, New York, NY 10029, USA. Louis.Aledort@mountsinai.org
D000906:Antibodies; D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000627:therapeutic use*; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D013927:Thrombosis / Q000139:chemically induced
D000906:Antibodies; D001779:Blood Coagulation Factors; C065655:anti-inhibitor coagulant complex